CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Newly established WGS recommendations published in the European Journal of Human Genetics

Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites…

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

A new collaborative research project has now been initiated, which may be used to validate rare genetic causes of neurogenerative diseases as…

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 22, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 08, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation

CAMBRIDGE, Mass. and ROSTOCK,…

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads